Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Curcumin + paclitaxel is a combination therapy that shows synergistic anticancer effects. Curcumin, a polyphenol derived from turmeric (Curcuma longa), enhances the therapeutic efficacy of paclitaxel, a conventional chemotherapeutic agent. This combination has demonstrated superior outcomes compared to paclitaxel alone in various cancer types, including breast, ovarian, and lung cancers. The synergistic effect works through multiple mechanisms, including downregulation of NF-κB, enhanced apoptosis induction, and regulation of the miR-9-5p/BRCA1 axis in ovarian cancer. Intravenous administration of curcumin overcomes its typically poor bioavailability when taken orally.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on curcumin + paclitaxel.